Novo Nordisk revenue and financials

NVO · NYSE · USD

Secondary listing. The primary listing is Novo Nordisk · Nasdaq Copenhagen (DKK)

$37.53Change from previous close: −0.03%Absolute change: −$0.01

Close · October 6, 2026

In the fiscal year ended December 2025, Novo Nordisk reported revenue of 309.06B id:6 (+6.43% year over year). Net income was 102.43B id:6, a net margin of 33.1%.

Annual revenue · 2025: 309.06B id:6
  1. 111.78B id:62016
  2. 111.7B id:62017
  3. 111.83B id:62018
  4. 122.02B id:62019
  5. 126.95B id:62020
  6. 140.8B id:62021
  7. 176.95B id:62022
  8. 232.26B id:62023
  9. 290.4B id:62024
  10. 309.06B id:62025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+6.43%
2025 vs 2024
Net income growth
+1.43%
2025 vs 2024
Net margin
33.1%
2024: 34.8%

Financial data

Amounts in millions of id:6; per-share values in id:6; shares in millions.

Cash flow · Annual
Item2025202420232022202120202019201820172016
Operating cash flow119,102120,968108,90878,88755,00051,95146,78244,61641,16848,314
Depreciation and amortization14,3488,2907,2896,5535,4525,4034,6793,9253,1823,193
Capital expenditure-60,140-47,164-25,806-12,146-6,335-5,825-8,932-9,636-7,626-7,068
Investing cash flow-79,158-128,895-43,892-24,918-31,605-22,436-11,509-12,080-6,571-6,790
Financing cash flow-28,4088,735-63,158-51,797-25,493-32,244-35,484-34,521-35,689-38,887
Dividends paid-51,763-44,140-31,767-25,303-21,517-20,121-19,409-19,048-18,844-23,830
Share repurchases-1,388-20,181-29,924-24,086-19,447-16,855-15,334-15,567-16,845-15,057
Debt issued103,93179,3910.011,21522,1605,68281.094.0——
Debt repaid-79,188-6,335-1,467-13,623-6,689-950-822———
Effect of exchange rates-727455-119-238591-456-7.044.0-211-26.0
Net change in cash10,8091,2631,7391,934-1,507-3,185-218-1,529-1,3032,611
Free cash flow58,96273,80483,10266,74148,665—————
Levered free cash flow37760,57354,54757,49643,89716,96426,78327,49221,36828,538